Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 8/20 | 0.40 |
| ▸ | CNR1 | P21554 | 7/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL846790 | 0.98 | CYP1A2 (0.39) | CYP1A2CNR2CNR1NAAAEPHX1 | |
| SCHEMBL12879484 | 0.86 | CYP1A2 (0.36) | CYP1A2CNR2CNR1EPHX1 | |
| SCHEMBL15628148 | 0.85 | — | — | |
| SCHEMBL15791376 | 0.85 | — | — | |
| SCHEMBL22006126 | 0.83 | CYP1A2 (0.32) | CYP1A2CNR2CNR1 | |
| SCHEMBL23014765 | 0.79 | SPHK2 (0.37) | CYP1A2CNR2CNR1EPHX2 | |
| SCHEMBL15915019 | 0.79 | CYP1A2 (0.44) | CYP1A2CNR2CNR1NAAAEPHX1 | |
| SCHEMBL3898468 | 0.79 | CYP1A2 (0.44) | CYP1A2CNR2CNR1NAAAEPHX1 | |
| SCHEMBL2614280 | 0.78 | SHBG (0.34) | CNR2CNR1EPHX1 | |
| SCHEMBL23014857 | 0.78 | CNR1 (0.35) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160067341-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067341-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CYP1A2 4799/4885CNR2 3085/4885CNR1 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.